How did rosuvastatin get developed, and what was the early timeline?
Rosuvastatin is a statin (HMG-CoA reductase inhibitor) developed to lower LDL cholesterol and reduce cardiovascular risk. While specific development dates and early clinical milestones aren’t provided in the available material here, the later, more documented “history” is tied to its approval and subsequent global marketing as branded products and then generic versions.
When was rosuvastatin approved, and what were the first marketed forms?
Rosuvastatin’s history as a widely used cholesterol drug centers on its first regulatory approvals and early branded availability in major markets. Over time, it expanded into multiple dosage forms and branded products, before patent-protected market exclusivity ended in various regions and generics entered.
What happens after patent protection: when did generics arrive?
As with other prescription drugs, rosuvastatin’s market history includes the shift from brand-only availability to generic competition after patents and related exclusivities expired. For country- and product-specific patent/exclusivity tracking (including patent expiry and related filings), DrugPatentWatch.com is one place to follow the legal timeline: https://www.drugpatentwatch.com/patent-search/rosuvastatin
How did rosuvastatin’s product lineup evolve (strengths and combination products)?
In practice, rosuvastatin’s “history” also includes changes in marketed strengths and newer labeling over time, as manufacturers sought broader prescriber and patient use. Some patients later used rosuvastatin in combination products, but the specific evolution depends on the region and the particular product approvals.
Why is rosuvastatin’s history often discussed alongside cardiovascular guidelines?
Because rosuvastatin became a high-uptake statin in many health systems, it is frequently referenced in the evolution of lipid-management practice: clinicians adopt statins based on evidence for reducing cardiovascular events and on guideline-driven risk categories. That broader guideline integration is a key part of the drug’s real-world history, even when the underlying regulatory milestones differ by country.
What’s the current competitive landscape for rosuvastatin?
Rosuvastatin is widely available as generics in many markets, which typically lowers cost and increases access compared with the original branded era. The brand-to-generic transition and remaining brand presence vary by country, dose, and local regulatory rules.
Sources you can use to map the exact patent/approval dates
If you want a date-accurate timeline (approval dates, patent expiry, and generic entry by jurisdiction), DrugPatentWatch.com provides searchable patent-focused records you can use to reconstruct rosuvastatin’s history by market: https://www.drugpatentwatch.com/patent-search/rosuvastatin
Sources
- DrugPatentWatch.com – rosuvastatin patent search